Floatz logo

SOLUBLE RECEPTOR FUSED TO PART OF AN ANTIBODY THAT IS DESIGNED TO BLOCK THE GROWTH FACTOR ACTIVIN A

Fallopian Tube Cancer

Santa Maria Biotherapeuticsprotein_peptidePhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

125 Active assets in the Fallopian Tube Cancer cohort.

Asset / SponsorPhaseRating
Mirvetuximab Soravtansine
AbbVie
Phase 3BB
Inno-206
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BB
Carboplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Hycamtin
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

SOLUBLE RECEPTOR FUSED TO PART OF AN ANTIBODY THAT IS DESIGNED TO BLOCK THE GROWTH FACTOR ACTIVIN A is also rated in:

endometrial carcinomaDormant
CC
Indicative ·
40 / 100
View asset →
neoplasmDormant
CC
Indicative ·
40 / 100
View asset →
ovarian cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →